Dette var tilfældet for alle HCV- genotyper, især genotype 1, i hvilken tilbagefaldsraten blev reduceret med 30% sammenlignet med interferon alfa- 2b- monoterapi.
This was true for all HCV genotypes, particularly Genotype 1, in which the relapse rate was reduced by 30% compared with interferon alfa-2b monotherapy.